Top

International Journal of Clinical Oncology

Published in:

01-10-2018 | Original Article

Multi-panel assay of serum autoantibodies in colorectal cancer

Authors: Mitsunori Ushigome, Yoshihiro Nabeya, Hiroaki Soda, Nobuhiro Takiguchi, Akiko Kuwajima, Masatoshi Tagawa, Kazuyuki Matsushita, Junichi Koike, Kimihiko Funahashi, Hideaki Shimada

Published in: International Journal of Clinical Oncology | Issue 5/2018

Abstract

Background

Although serum p53 autoantibodies (s-p53-Abs) are induced even in the early stages of colorectal cancer, their positive rate is only approximately 20%. Therefore, we assessed the possibility of using other serum autoantibodies to increase the positive rates for detecting colorectal cancer.

Methods

Autoantibodies against 17 tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, NY-ESO-1, p90, Sui1, HSP40, CyclinB1, HCC-22-5, c-myc, PrxVI, VEGF, HCA25a, p62, and Annexin II) were evaluated in 279 patients with colorectal cancer and 74 healthy controls. Cutoff values were fixed at mean + 3 standard deviations of serum titers in healthy controls.

Results

Autoantibodies with the highest positive rates were p53 (20%), RalA (14%), HSP70 (12%), and Galectin1 (11%). Combination assays using multiple autoantibodies increased the positive rates based on the number of autoantibodies used. Positive rates of 56, 62, 66, 71, and 73% were obtained with 6, 9, 11, 14, and 17 antibodies, respectively, for the overall disease. Moreover, these autoantibodies showed relatively high positive rates even during stage 0/I disease (55 and 70% with 6 and 17 antibodies, respectively).

Conclusion

The measurement of set of 17 autoantibodies allowed autoantibody profiling in patients with colorectal cancer. The combination assay of six tumor antigens (p53, RalA, HSP70, Galectin1, KM-HN-1, and NY-ESO-1) achieved a positive rate of 56%. Such high positive rates will be helpful for detecting colorectal cancer regardless of tumor stages.

Das V, Kalita J, Pal M (2017) Predictive and prognostic biomarkers in colorectal cancer: a systematic review of recent advances and challenges. Biomed Pharmacother. 87:8–19CrossRef

Suzuki T, Shimada H, Ushigome M et al (2016) Three-year monitoring of serum p53 antibody during chemotherapy and surgery for stage IV rectal cancer. Clin J Gastroenterol 9(2):55–58CrossRef

Hoshino I, Nagata M, Takiguchi N et al (2017) Panel of autoantibodies against multiple tumor-associated antigens for detecting gastric cancer. Cancer Sci 108:308–315CrossRef

Ochiai H, Ohishi T, Osumi K et al (2012) Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today 42:164–168CrossRef

Yamaguchi T, Takii Y, Maruyama S (2014) Usefulness of serum p53 antibody measurement in colorectal cancer: an examination of 1384 primary colorectal cancer patients. Surg Today 44:1529–1535CrossRef

Li Y, Karjalainen A, Koskinen H et al (2005) p53 autoantibodies predict subsequent development of cancer. Int J Cancer 114:157–160CrossRef

Trivers GE, De Benedetti VM, Cawley HL et al (1996) Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 2:1767–1775PubMed

Saito F, Shimada H, Ogata H et al (2017) Detection of the early phase of esophageal cancer progression into lamina propria mucosae by the serum p53 antibody. Esophagus 1:1–4

Xu YW, Peng YH, Chen B et al (2014) Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol 109(1):36–45CrossRef

10.

Lin LH, Xu YW, Huang LS et al (2017) Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma. Clin Proteomics 1(14):6CrossRef

11.

Chen H, Werner S, Butt J et al (2016) Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting. Oncotarget 29(7):16420–16432

12.

Negm OH, Hamed MR, Schoen RE et al (2016) Human blood autoantibodies in the detection of colorectal cancer. PLoS One 11(7):e0156971CrossRef

13.

Okada R, Shimada H, Tagawa M et al (2017) Profiling of serum autoantibodies in Japanese patients with hepatocellular carcinoma. Toho J Med 3(3):84–92

14.

Nanami T, Shimada H, Yajima S et al (2016) Clinical significance of serum autoantibodies against Ras-like GTPases RalA in patients with esophageal squamous cell carcinoma. Esophagus 13:167–172CrossRef

15.

Shiratori F, Shimada H, Nagata M et al (2016) Serum galectin-1 autoantibodies in patients with hepatocellular carcinoma. Toho J Med 2:67–72

16.

Oshima Y, Shimada H, Yajima S et al (2016) NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers. J Gastroenterol 51:30–34CrossRef

17.

Edge SB, Byrd DR, Compton CC et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York

18.

Zhang JY, Casiano CA, Peng XX et al (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12:136–143PubMed

19.

Boyle P, Chapman CJ, Holdenrieder S et al (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22:383–389CrossRef

20.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’for medical statistics. Bone Marrow Transplant 48:452–458CrossRef

21.

Shimada H, Hoshino T, Okazumi S et al (2002) Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of esophageal squamous cell carcinoma. Br J Cancer 86:552–557CrossRef

22.

Tokunaga R, Sakamoto Y, Nakagawa et al (2017) The utility of tumor marker combination, including serum P53 antibody, in colorectal cancer treatment. Surg Today 47:636–642CrossRef

23.

Shimada H, Shiratori T, Takeda A et al (2009) Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 33:272–277CrossRef

Title: Multi-panel assay of serum autoantibodies in colorectal cancer
Authors: Mitsunori Ushigome
Yoshihiro Nabeya
Hiroaki Soda
Nobuhiro Takiguchi
Akiko Kuwajima
Masatoshi Tagawa
Kazuyuki Matsushita
Junichi Koike
Kimihiko Funahashi
Hideaki Shimada
Publication date: 01-10-2018
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 5/2018
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1278-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2018

Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma

Treatment outcomes of patients with spinal metastases derived from hepatocellular carcinoma

Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Analysis of unexplained carcinoembryonic antigen elevation after curative treatment of locally advanced rectal cancer

Validation of the 8th edition of the AJCC/UICC TNM staging system for tongue squamous cell carcinoma

Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer